Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 28

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

189

HTML

1951

Figures (1-7)

311

Sum=2451

Jul 28, 2005 (publication date) through Nov 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Colorectal Cancer

World J Gastroenterol. Jul 28, 2005; 11(28): 4332-4336
Published online Jul 28, 2005. doi: 10.3748/wjg.v11.i28.4332

Full Size Figure Download Figure

Figure 5 Time course of in vivo VEGF serum levels of tumor bearing mice that had been treated with AdLacZ or AdsFlt1-3 (mean±SE).

Citation: Schmitz V, Kornek M, Hilbert T, Dzienisowicz C, Raskopf E, Rabe C, Sauerbruch T, Qian C, Caselmann WH. Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice. World J Gastroenterol 2005; 11(28): 4332-4336
URL: https://www.wjgnet.com/1007-9327/full/v11/i28/4332.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i28.4332